Alnylam, Isis JV Regulus to Tackle MicroRNA
This article was originally published in Start Up
Executive Summary
Isis and Alnylam have entered a joint venture in microRNA technology and therapeutics called Regulus. The company's first product candidate will be a next-generation antisense therapy against miR122, a microRNA involved in hepatitis C virus replication.
You may also be interested in...
Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work
RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.
Start-Up Quarterly Statistics, Q2 2010
Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.
Start-Up Quarterly Statistics, Q2 2010
Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.